Corcept Soars as Ovarian Cancer Drug Succeeds Late-Stage Trial
** Shares of drugmaker Corcept Therapeutics soar 91.4% to $104.55 premarket
** CORT says its experimental drug for ovarian cancer in combination with chemotherapy met the main goal of a late-stage trial
** Co says the drug, relacorilant, when combined with chemotherapy agent nab-paclitaxel, showed a 30% reduction in disease-progression risk in platinum-resistant ovarian cancer patients, compared to those treated with chemotherapy alone
** Platinum-resistant ovarian cancer is a type of ovarian cancer that doesn't responds to platinum-based chemotherapy treatments, which are typically used as a first-line therapy
** As of last close, CORT shares rise up 8.4% YTD
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10